US biotech giant Moderna Inc declared that its COVID-19 shot was about 93% effective through six months after the second dose, demonstrating hardly any change from the 94% efficacy reported in its original clinical trial.
Such a percentage of the drug's effectiveness was recorded at the start of clinical trials. Nowadays, this indicator has remained practically unchanged.
In the second quarter of 2021, Moderna's sales amounted to $4.4 billion, slightly exceeding analysts' forecasts. They had expected the figure to total $4.2 billion. At the same time, the profit reached $2.78 billion, or $6.46 per share (versus the forecast value of $5.96 per share). For the same period in 2020, the sales volume of Moderna came in at $67 million.
In the period from August 2 to 6, other leading pharmaceutical companies, Pfizer and Biotech, also confirmed the effectiveness of their vaccines. However, they noticed a gradual decrease in their efficacy (up to 84%) within six months after the second dose.
